TABLE 1.
Characteristics of Multiple Endocrine Neoplasia Type 1 Patients Who Underwent Surgery
| Patient | Age at NF-PET Diagnosis (yr) | Interval to Surgery (yr) | Indication for Surgery | Surgery | f/u After Surgery (yr) | Last f/u |
| 1 | 51.2 | 9.1 | Increase in size (max 29 mm) | DSP | 6.3 | 2 New NF-PET (max 4 mm) PP normal, NIDDM |
| 2 | 34.1 | 11.5 | Increase in size (max 25 mm) | Whipple + enucleation, 1LN + /7LN | 3.4 | 3 NF-PET (max 15 mm), no evidence of LN or distant mets |
| 3 | 49.4 | 11.2 | ZES, NF-PET stable in size | Whipple (4 gastrinoma, 1LN + /1LN) | 1.2 | Persistent hypergastrinemia, no evidence of LN or distant metastasis |
| 4 | 30.4 | 4.8 | Symptomatic VIPoma | DSP + enucleation | 3.9 | NIDDM, biochemically cured of VIPoma, no evidence of tumor on MRI |
| 5 | 59.3 | 3.2 | Hepatic metastasis (8 mm) | DSP + enucleation + left hepatic lobectomy 0LN + /6LN | 5.1 | No evidence of tumor on CT |
| 6 | 42.5 | 1.0 | Increase in size (max 25 mm) | Body + tail resection | 8.3 | 3 new NF-PET (max 4 mm), PP normal |
| 7 | 36.2 | 1.0 | Insulinoma + increase in size (max 22 mm) | Body + tail resection + enucleation of 8 tumors | 6.8 | NIDDM, biochemically cured of insulinoma, no new tumor on MRI |
Number of positive LN/number of resected LN.
DSP indicates distal splenopancreatectomy; f/u, follow-up; LN, lymph node; max, maximum size; NIDDM, non–insulin-dependent diabetes mellitus.